Last updated: August 9, 2026
Risedronate sodium is an established oral bisphosphonate with limited systemic absorption, strict administration requirements, and broad generic competition. The strongest excipient opportunities are in adherence, food-tolerant dosing, gastrointestinal tolerability, dose flexibility, and differentiated delivery rather than in conventional immediate-release tablets.
The commercial baseline is low-cost generic risedronate sodium. The main differentiated reference product is Atelvia, a delayed-release 35 mg tablet designed for administration immediately after breakfast. Any new product must overcome the active ingredient's absorption sensitivity to food and polyvalent cations while meeting FDA requirements for bioavailability, dosage-form performance, and labeling.
What is risedronate sodium used for?
Risedronate sodium is an oral nitrogen-containing bisphosphonate indicated for osteoporosis and other disorders involving abnormal bone resorption. In the United States, labeled uses include:
- Treatment and prevention of postmenopausal osteoporosis
- Treatment of osteoporosis in men
- Glucocorticoid-induced osteoporosis
- Paget's disease of bone
Risedronate binds to hydroxyapatite in bone and inhibits osteoclast-mediated bone resorption. The therapeutic dose is small, but absorption is very low. The immediate-release product has an absolute oral bioavailability of approximately 0.6% under fasting conditions, and absorption falls substantially when administered with food or beverages other than water [1].
This creates a formulation paradox. The low dose limits the amount of excipient required, but the narrow administration window makes excipient selection commercially important.
Which risedronate sodium products are marketed?
Immediate-release risedronate tablets
Immediate-release tablets have been marketed in strengths including 5 mg, 30 mg, 35 mg, 75 mg, and 150 mg. The 35 mg once-weekly regimen is a major generic format. Monthly 150 mg dosing is another adherence-oriented format.
Immediate-release products generally require patients to:
- Take the tablet with plain water.
- Take it before food or other medicines.
- Remain upright for at least 30 minutes.
- Avoid calcium, iron, magnesium, aluminum, and other polyvalent cations during the relevant dosing interval.
Atelvia delayed-release tablets
Atelvia is a delayed-release 35 mg risedronate sodium tablet administered once weekly immediately after breakfast. Its commercial proposition is convenience and improved alignment with patient routines rather than increased potency.
The delayed-release design separates tablet disintegration and active release from the upper gastrointestinal environment. The product still carries strict instructions regarding calcium-containing food and supplements, and its clinical benefit depends on maintaining adequate exposure [2].
Generic products
Multiple abbreviated new drug applications have supported generic immediate-release risedronate sodium tablets. Generic competition has reduced the price of standard tablets and limits the commercial value of an undifferentiated excipient change.
A new formulation therefore needs a meaningful product attribute, such as:
- Reduced fasting burden
- Improved esophageal or gastric tolerability
- Smaller tablet size
- Easier swallowing
- Flexible dosing
- Improved packaging and adherence
- Lower interaction risk with mineral supplements
- A pediatric, geriatric, or institutional-care presentation where clinically appropriate
What excipients are used in risedronate sodium tablets?
Reference and generic risedronate tablets use conventional solid-dose excipients. Common inactive ingredients include:
- Microcrystalline cellulose
- Lactose monohydrate
- Crospovidone
- Hypromellose
- Magnesium stearate
- Colloidal silicon dioxide
- Polyethylene glycol
- Titanium dioxide and other coating materials
The exact composition varies by manufacturer and strength. FDA labeling and DailyMed records should control the final composition assessment for a specific product [1, 3].
Why excipient selection matters
Risedronate is highly sensitive to binding and complexation. Calcium, magnesium, iron, and aluminum can reduce absorption through formation of poorly absorbed complexes. This has several formulation implications:
- Calcium-containing excipients are generally unattractive for an oral risedronate product.
- Mineral-containing colorants and functional excipients require careful assessment.
- Multivalent-ion contamination from processing equipment or packaging may be relevant.
- Excipients that alter gastric emptying or create prolonged intestinal residence can change exposure.
- Lubricant level and hydrophobicity can affect wetting and dissolution.
The excipient strategy should therefore prioritize chemical compatibility, low extractables, low moisture sensitivity, rapid and reproducible dissolution, and minimal interaction with the active ingredient.
How should an immediate-release risedronate formulation be optimized?
The most defensible immediate-release strategy is a low-complexity, low-risk tablet platform.
Core tablet design
A typical platform can use:
- Microcrystalline cellulose as a diluent and compression aid
- Crospovidone as a superdisintegrant
- A low concentration of magnesium stearate as lubricant
- Colloidal silicon dioxide for flow improvement
- A film coat based on hypromellose and polyethylene glycol
The principal development variables are not novel excipient identity but the ratio, grade, and processing sequence. Excessive lubricant can slow wetting and dissolution. Excessive coating weight can delay disintegration. High compression force can create a hard tablet that fails to disperse rapidly.
Commercial opportunity
An immediate-release product can gain modest differentiation through:
- A smaller 35 mg weekly tablet
- A low-force, orally disintegrating tablet
- A scored tablet for selected dose regimens
- A swallowability-focused film coat
- A blister system that links weekly dosing to calendar days
- A preservative-free liquid or unit-dose suspension for institutional use
An orally disintegrating tablet is technically challenging because rapid disintegration does not remove the need for water-free or food-sensitive administration. The product may improve swallowing, but it must not encourage administration with food or beverages that reduce absorption.
What excipients are appropriate for delayed-release risedronate?
Delayed-release risedronate requires a multipart functional system rather than a simple enteric coat.
Possible architecture
A delayed-release tablet may include:
- An immediate tablet core containing risedronate sodium.
- A seal coat that separates the active core from the functional polymer.
- An enteric or pH-dependent coating.
- A protective outer film coat.
- Excipients that control coat integrity, flexibility, and moisture protection.
Suitable polymers may include methacrylic acid copolymers, hypromellose phthalate, hypromellose acetate succinate, or other approved enteric materials, subject to the target release profile and regulatory precedent.
The formulation must balance:
- Protection during gastric transit
- Release at the intended intestinal pH
- Reproducible dissolution across fed-state conditions
- Mechanical stability during packaging and shipping
- Resistance to cracking and dose dumping
- Compatibility with the low-dose active ingredient
Key development risk
The fed-state performance of a delayed-release product is central to its value. Food changes gastric residence time, pH, bile exposure, and intestinal transit. A formulation that performs well in a simple buffer may fail under biorelevant fed-state testing.
A commercially credible program should characterize dissolution under multiple pH stages and fed-state media, including conditions that simulate delayed gastric emptying and high-fat meals. FDA's product-specific guidance and relevant biopharmaceutics principles should guide the study design [4].
What formulation patents protect risedronate products?
The original risedronate compound and early oral formulations are no longer strong barriers to generic immediate-release entry. Actonel's primary commercial exclusivity has expired, and immediate-release risedronate is available from multiple generic manufacturers.
The more relevant intellectual-property categories are:
- Delayed-release tablet architecture
- Enteric polymer combinations
- Coating sequence and thickness
- Fed-state release profiles
- Specific dosing regimens
- Combination products with calcium or vitamin D
- Packaging and adherence systems
- Manufacturing controls that produce a defined release profile
Atelvia's delayed-release technology was protected by product and formulation patents during its market exclusivity period. The economic value of any remaining patent position depends on the specific patent, claims, terminal disclaimer, Orange Book listing, and litigation history. Patent protection for the active ingredient does not automatically protect a redesigned excipient system.
Patent strategy for a new formulation
A new sponsor should claim the formulation at several levels:
- Composition claims directed to the active, polymer, plasticizer, and coating system
- Layered dosage-form claims
- Dissolution-profile claims
- Fed-state release claims
- Manufacturing-process claims
- Stability and moisture-protection claims
- Method-of-use claims tied to administration after food or reduced dosing burden
The strongest claims are usually tied to measurable performance or a defined structural relationship among layers. Broad claims covering routine use of standard enteric polymers face validity and obviousness pressure.
When does risedronate sodium lose exclusivity?
Standard immediate-release risedronate sodium has already lost meaningful market exclusivity in the United States. Generic products compete on price, supply reliability, manufacturing quality, and pharmacy contracting.
The commercial timeline is:
| Milestone |
Commercial effect |
| Actonel approval |
Established the branded oral bisphosphonate market |
| Generic immediate-release entry |
Reduced price and eliminated broad product-level exclusivity |
| Atelvia approval |
Created a delayed-release, post-breakfast dosing option |
| Atelvia patent and exclusivity period |
Protected a differentiated formulation for a limited period |
| Current market |
Generic immediate-release competition with limited branded differentiation |
FDA's Orange Book remains the controlling source for current listed patents, pediatric exclusivity, and regulatory exclusivity associated with a specific approved application [5].
What is the Orange Book status of risedronate sodium?
The Orange Book separates approved application information from patent and exclusivity information. For risedronate sodium, the principal business conclusion is that standard immediate-release products are exposed to generic competition.
A sponsor assessing a new product should review:
- The reference listed drug for the proposed dosage form
- Current patent listings for Actonel and Atelvia
- Any listed method-of-use patents
- Paragraph IV certifications filed against listed patents
- Approved strengths and dosage forms
- Whether a proposed delayed-release product requires an ANDA or a 505(b)(2) application
A formulation that differs materially from an approved immediate-release tablet may not fit a conventional ANDA pathway. A delayed-release, food-enabled, chewable, liquid, or modified-release product may require a 505(b)(2) application supported by bridging pharmacokinetic and clinical evidence.
Which companies are challenging or competing with risedronate sodium?
The competitive landscape includes:
- Generic manufacturers of risedronate sodium tablets
- Teva Pharmaceutical Industries
- Mylan and successor Viatris operations
- Endo and other historical generic suppliers
- Large contract manufacturers and regional suppliers
- Competing osteoporosis products from Merck, Amgen, Eli Lilly, and other companies
The main therapeutic competitors are:
| Product |
Active ingredient |
Route |
Commercial differentiation |
| Generic risedronate |
Risedronate sodium |
Oral |
Low price |
| Actonel |
Risedronate sodium |
Oral |
Historical brand and dosing breadth |
| Atelvia |
Risedronate sodium |
Oral delayed release |
Post-breakfast weekly dosing |
| Fosamax/generic alendronate |
Alendronate sodium |
Oral |
Established low-cost bisphosphonate |
| Boniva/generic ibandronate |
Ibandronate sodium |
Oral or injectable |
Monthly oral or intermittent dosing |
| Reclast |
Zoledronic acid |
Intravenous |
Annual administration |
| Prolia |
Denosumab |
Subcutaneous |
Six-month administration |
| Evenity |
Romosozumab |
Subcutaneous |
Anabolic and antiresorptive profile |
The commercial ceiling for a new risedronate product is constrained by low-cost oral alternatives and injectable therapies that remove weekly administration from the patient.
What generic entry risks exist for a new risedronate formulation?
Generic entry risk is high for a conventional immediate-release tablet. The active ingredient is old, the dosage strengths are established, and the excipient platform is conventional.
Risk is lower, but not eliminated, for:
- Delayed-release products
- Orally disintegrating products
- Novel multiparticulates
- Products with clinically supported food tolerance
- Products with a new administration schedule
- Combination products with clinically meaningful adherence benefits
A delayed-release product may still face an abbreviated pathway if the FDA determines that the proposed product is sufficiently equivalent to the reference product. A 505(b)(2) pathway can provide regulatory flexibility, but it does not guarantee durable market protection.
Patent risk is highest where the formulation relies on well-known enteric polymers and routine coating methods. Commercial differentiation should therefore include clinical or human-factors evidence, not only a new excipient list.
How can excipients create commercial opportunities?
1. Food-tolerant dosing
The highest-value opportunity is a formulation that preserves clinically adequate exposure when taken with a normal meal. This is difficult because food has a major effect on risedronate absorption. A successful product could reduce the fasting burden and improve persistence.
The excipient system would need to control release and protect the active until the intended absorption environment. The formulation claim should be supported by fed-state pharmacokinetics and clinically relevant dosing instructions.
2. Gastrointestinal tolerability
Risedronate labeling includes warnings regarding upper gastrointestinal irritation and esophageal reactions [1]. A formulation that reduces direct esophageal exposure or avoids prolonged contact with the upper gastrointestinal tract may support differentiation.
Potential approaches include:
- Delayed release
- Rapid dispersion with controlled transit
- Reduced tablet adhesion
- Improved coating integrity
- A swallowability-focused dosage form
A tolerability claim requires clinical evidence. Excipients alone do not establish a lower adverse-event rate.
3. Adherence packaging
Packaging is a lower-risk opportunity than a new release mechanism. Weekly and monthly regimens are vulnerable to missed doses and improper administration.
Commercial concepts include:
- Calendarized blister cards
- Integrated reminder labels
- Unit-dose moisture protection
- Pharmacy-ready adherence packs
- Packaging that separates risedronate from calcium and iron supplements
These features may support commercial positioning but generally provide weaker patent protection than a technically differentiated dosage form.
4. Institutional and geriatric formats
Some patients have difficulty swallowing conventional tablets or complying with upright-posture instructions. A liquid, dispersible, or orally disintegrating format could target long-term-care and home-health settings.
The regulatory risk is substantial. A liquid formulation could increase mucosal exposure, alter dosing accuracy, and create stability challenges. The product would need packaging that limits dosing errors and prevents contact with incompatible minerals.
What manufacturing and IP barriers affect risedronate excipient development?
Manufacturing barriers are moderate for immediate-release tablets and high for delayed-release products.
Immediate-release barriers
Key controls include:
- Uniform low-dose drug distribution
- Prevention of segregation
- Content uniformity
- Moisture control
- Lubrication control
- Fast dissolution
- Removal of metal-ion contamination risks
Delayed-release barriers
The major controls include:
- Core weight and hardness
- Seal-coat uniformity
- Enteric polymer application
- Coating weight gain
- Residual solvent and moisture
- Mechanical resistance
- Dissolution after storage
- Fed-state performance
These manufacturing parameters can support process patents and trade secrets. A sponsor should protect coating equipment settings, spray conditions, polymer grades, curing conditions, and in-process testing through a combination of patents and confidential know-how.
How strong is the risedronate sodium patent estate?
The patent estate is weak for ordinary immediate-release tablets and materially stronger for genuinely differentiated delivery systems.
| Product or strategy |
Patent strength |
Generic risk |
Commercial outlook |
| Conventional 35 mg tablet |
Low |
High |
Price-driven |
| Smaller or easier-to-swallow tablet |
Low to moderate |
High |
Limited premium |
| Orally disintegrating tablet |
Moderate |
Moderate to high |
Niche opportunity |
| Delayed-release tablet |
Moderate |
Moderate |
Strongest formulation opportunity |
| Food-tolerant formulation |
Moderate to strong if clinically validated |
Moderate |
Potential premium |
| Liquid or dispersible product |
Moderate |
Moderate |
Institutional and geriatric niche |
| Adherence packaging |
Low |
High |
Fast, low-cost differentiation |
The strongest commercial model is a delayed-release or food-tolerant product supported by a defensible formulation patent, a 505(b)(2) regulatory strategy, and evidence of improved adherence or tolerability.
What licensing opportunities exist for risedronate sodium?
Licensing opportunities are most credible in three areas:
- Enteric coating and controlled-release technology
- Oral dosage-form platforms for low-bioavailability drugs
- Adherence packaging and digital medication management
A licensee should avoid paying a premium for a conventional excipient combination that generic manufacturers can reproduce. The value should be tied to one or more of the following:
- Issued claims with meaningful remaining term
- FDA precedent for the dosage-form pathway
- Human pharmacokinetic data
- Fed-state performance
- Clinical adherence data
- Manufacturing know-how that is difficult to replicate
The absence of active ingredient exclusivity means the license must monetize product differentiation, regulatory efficiency, manufacturing reliability, or market access.
Key Takeaways
- Risedronate sodium is a mature oral bisphosphonate with high generic exposure.
- Conventional immediate-release tablets offer limited formulation and pricing opportunity.
- The most attractive excipient strategy is delayed release or food-tolerant dosing.
- Calcium, magnesium, iron, and aluminum interactions constrain excipient selection.
- Crospovidone, microcrystalline cellulose, hypromellose, silicon dioxide, magnesium stearate, lactose, and coating polymers are established platform materials.
- A new product should pursue measurable release, fed-state, tolerability, or adherence advantages.
- The likely regulatory pathway depends on how substantially the dosage form differs from the reference product.
- Patent strength is weak for routine tablets and stronger for validated delayed-release architectures.
- Commercial success requires more than a novel excipient list because generic manufacturers can reproduce standard compositions.
- The principal opportunity is a differentiated product with a defensible formulation patent and clinically supported administration advantage.
FAQs
Can calcium be used as an excipient in a risedronate sodium tablet?
Calcium is generally unattractive because polyvalent cations can bind risedronate and reduce absorption. A calcium-containing combination product would require a formulation that physically and temporally separates the ingredients and demonstrates adequate bioavailability.
Is an enteric-coated risedronate tablet automatically patentable?
No. Enteric coating is a well-established technique. Patentability depends on the specific polymer system, layer structure, process, release profile, and demonstrated technical effect.
Could risedronate sodium be developed as an oral solution?
Yes, but the format raises stability, dosing accuracy, mucosal exposure, packaging, and mineral-interaction issues. An oral solution would need a clear clinical and regulatory rationale.
Does a smaller risedronate tablet justify a premium price?
Usually not by itself. A smaller tablet may improve swallowing and adherence, but payers and generic competitors may treat size reduction as a limited benefit unless supported by human-factors or persistence data.
Is biosimilar competition relevant to risedronate sodium?
No. Risedronate sodium is a small-molecule drug, so the relevant competitive pathway is generic substitution through ANDAs, not biosimilar development under the Public Health Service Act.
References
-
U.S. Food and Drug Administration. (2023). Risedronate sodium tablets: Prescribing information. FDA/DailyMed.
-
U.S. Food and Drug Administration. (2023). Atelvia (risedronate sodium) delayed-release tablets: Prescribing information. FDA/DailyMed.
-
National Library of Medicine. (2024). DailyMed: Risedronate sodium tablet inactive ingredients and labeling. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2022). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
